News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
16,469 Results
Type
Article (900)
Company Profile (3)
Press Release (15566)
Section
Business (3640)
Career Advice (5)
Deals (533)
Drug Development (5311)
Employer Resources (1)
FDA (497)
Job Trends (706)
News (9488)
Policy (726)
Tag
Academia (42)
Alliances (1075)
Alzheimer's disease (43)
Antibody-drug conjugate (ADC) (16)
Approvals (514)
Artificial intelligence (4)
Best Places to Work (744)
Bladder cancer (8)
Brain cancer (4)
Breast cancer (49)
Cancer (325)
Career advice (5)
CAR-T (7)
Cell therapy (20)
Cervical cancer (4)
Clinical research (4630)
Collaboration (29)
COVID-19 (63)
C-suite (5)
Data (138)
Diabetes (3)
Diagnostics (49)
Earnings (1606)
Events (2804)
Executive appointments (11)
FDA (547)
Funding (12)
GLP-1 (13)
Government (90)
Healthcare (380)
Indications (4)
Infectious disease (67)
Inflammatory bowel disease (3)
Influenza (3)
Intellectual property (4)
IPO (339)
Job creations (18)
Job search strategy (3)
Layoffs (4)
Legal (44)
Liver cancer (20)
Lung cancer (70)
Lymphoma (24)
Manufacturing (5)
Medical device (192)
Medtech (192)
Mergers & acquisitions (201)
Metabolic disorders (5)
Neuroscience (47)
NextGen: Class of 2025 (127)
Non-profit (50)
Northern California (72)
Ovarian cancer (14)
Pancreatic cancer (18)
Patents (4)
Patient recruitment (6)
People (868)
Phase I (1229)
Phase II (1974)
Phase III (2074)
Pipeline (46)
Postmarket research (78)
Preclinical (343)
Prostate cancer (15)
Radiopharmaceuticals (9)
Real estate (39)
Regulatory (706)
Research institute (50)
Southern California (71)
Startups (51)
United States (648)
Vaccines (21)
Date
Today (2)
Last 7 days (20)
Last 30 days (98)
Last 365 days (1457)
2025 (164)
2024 (1477)
2023 (1592)
2022 (1751)
2021 (1746)
2020 (1568)
2019 (1317)
2018 (1056)
2017 (949)
2016 (863)
2015 (918)
2014 (611)
2013 (449)
2012 (336)
2011 (346)
2010 (240)
Location
Africa (9)
Asia (1362)
Australia (334)
California (167)
Canada (81)
China (40)
Colorado (14)
Connecticut (10)
Delaware (20)
Europe (3546)
Florida (13)
Illinois (10)
Indiana (12)
Japan (16)
Maryland (20)
Massachusetts (95)
Minnesota (9)
Montana (9)
New Jersey (98)
New York (87)
North Carolina (16)
Northern California (72)
Pennsylvania (26)
South America (11)
Southern California (71)
Texas (19)
Utah (11)
Washington State (15)
16,469 Results for "ose immunotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
January 14, 2025
·
5 min read
Press Releases
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
December 3, 2024
·
8 min read
Press Releases
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
January 30, 2025
·
5 min read
Business
OSE Immunotherapeutics Provides Business and Corporate Update
OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.
May 30, 2024
·
12 min read
Press Releases
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
July 1, 2024
·
9 min read
Business
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics SA, announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.
June 24, 2024
·
6 min read
Business
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
OSE Immunotherapeutics SA announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.
June 19, 2024
·
15 min read
Press Releases
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
February 20, 2025
·
6 min read
Press Releases
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
January 28, 2025
·
4 min read
Press Releases
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
December 11, 2024
·
6 min read
1 of 1,647
Next
